Thermal Ablation Followed by Immunotherapy for HCC
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of immunotherapy
toripalimab (anti-PD-1 mAb) combined with thermal ablation in patients with Hepatocellular
Carcinoma (HCC).